Recovery and Quality of Life in Cervical Cancer Patients Using Vaginal Dilators After Radiotherapy

This study investigates the longitudinal recovery trajectory and clinical predictors of Quality of Life (QoL) and vaginal morbidity in patients with cervical cancer following definitive radiation therapy. While combined External Beam Radiation Therapy (EBRT) and Intracavitary Radiation Therapy (ICRT/Brachytherapy) are highly effective for cancer control, they frequently lead to long-term physical sequelae, most notably radiation-induced vaginal stenosis and contraction. These changes can significantly impair sexual function and overall patient well-being.

Study Objectives and Design The research utilized a longitudinal design to track a cohort of 67 patients (mean age 51·75 ± 13·23 years) over a 12-month period. The primary objectives were to identify the clinical factors that predict the recovery of functional QoL domains.

Patients were assessed at six distinct time points: baseline (pre-treatment) and at 1, 3, 6, 9, and 12 months post-radiotherapy. QoL was measured using standardized instruments, including the EORTC QLQ-C30 (general health and functioning) and the EORTC QLQ-CX24 (cervical cancer-specific symptoms).

Clinical Predictors of Recovery

The study identifies several key independent variables that serve as predictors for post-treatment outcomes:

Time Post-Treatment: Time is a highly significant predictor for nearly all QoL domains. Acute symptoms (such as nausea, diarrhea, and fatigue) typically show the most dramatic improvement within the first 1 to 3 months.

Functional Stabilization: Functional domains, including physical and role functioning, show progressive improvement and typically peak and stabilize by the 6-to-12-month mark. Global QoL scores generally reach their highest stable levels (median 83·33) by 6 months post-treatment.

Baseline Clinical Factors: Factors such as clinical stage (with Stage IIIC1 being the most prevalent at 28·79%) and tumor extension to the upper vagina (present in 61·19% of the cohort) influence the starting QoL scores and the overall slope of the recovery curve.

Symptom Resolution and Functional Gains

Longitudinal analysis revealed significant improvements across multiple QoL metrics compared to baseline:

Symptom Burden: Scores for Fatigue, Nausea/Vomiting, and Diarrhea decreased significantly across all follow-up time points (P<0⋅001).

Functional Domains: Significant gains were sustained in Physical, Role, and Social functioning beginning as early as 1 to 3 months post-treatment.

Cervical Cancer-Specific Symptoms: The specific symptom burden (QLQ-CX24) dropped sharply and remained low throughout the year. Sexual function and vaginal aspect scores showed significant improvements later in the recovery process, specifically between 6 and 12 months.

In conclusion, this study demonstrates that while radiation therapy causes significant initial morbidity, the recovery of QoL follows a predictable timeline influenced primarily by time and adherence to vaginal dilator therapy. The dilator acts as a critical intervention to maintain anatomical integrity while the patient's functional roles and energy levels are restored over the first year of survivorship.

Inclusion criteria

• A confirmed diagnosis of cervical cancer, including various histological types such as Squamous cell carcinoma (85.07%), Adenocarcinoma (13.43%), or Small cell carcinoma.
• Completion of definitive radiation therapy, specifically the combination of External Beam Radiation Therapy (EBRT) and Intracavitary Radiation Therapy (ICRT/Brachytherapy).
• Participants identified as female.
• Patients were included across clinical stages I through IV, with Stage IIIC1 being the most common (28.79%).
• Willingness to participate in a 12-month longitudinal study involving assessments at six distinct time points: baseline (pre-treatment) and 1, 3, 6, 9, and 12 months post-radiotherapy.

Exclusion criteria

• Presence of lesions that make it impossible to use the vaginal dilator device.
• Chronic or severe bleeding that prevents the safe or effective use of the vaginal dilator.
• Emergency medical conditions or a clinical necessity for alternative treatments following the initial radiation therapy.
• Inability to attend follow-up visits or comply with the monitoring guidelines established in the study protocol.

Additionally, the sources define discontinuation criteria for participants who have already entered the study:

• The participant requests to withdraw from the project for any reason.
• The participant receives incomplete treatment due to the progression or specific nature of the disease.